



Additional file 3. HPVposVSCC have better overall survival compared to HPVnegVSCC. Kaplan-Meier curves showing overall survival (left) and the recurrence free period (RFP; right) for VSCC patients with HPVposVSCC (green), HPVnegVSCC/p53wt (blue) and HPVnegVSCC/p53abn (red). Statistical significance of the survival distribution was analyzed by log-rank testing. Significant differences between the overall survival of HPVposVSCC and HPVnegVSCC/p53wt (HR=0.14 (95% CI 0.02-0.80), $p=0.03$) or HPVnegVSCC/p53abn (HR=0.15 (95% CI 0.03-0.87), $p=0.04$) is observed. Comparison of the RFP showed similar differences between the groups. HPVposVSCC have better clinical outcome than HPVnegVSCC/p53wt (HR=0.48 (95% CI 0.14-1.60), $p=0.25$) and HPVnegVSCC/p53abn (HR=0.41 (95% CI 0.14-1.24), $p=0.11$).